The Health Care Burden of Hepatic Encephalopathy
- PMID: 32245532
- DOI: 10.1016/j.cld.2020.01.006
The Health Care Burden of Hepatic Encephalopathy
Abstract
Hepatic encephalopathy is a major neuropsychiatric complication of liver disease that affects 30% to 40% of cirrhotic patients. Hepatic encephalopathy is characterized by a brain dysfunction that is associated with neurologic complications. Those complications are associated with cognitive impairments, which negatively impacts patients' physical and mental health. In turn, hepatic encephalopathy poses a substantial economic and use burdens to the health care system. This article reviews the multidimensional aspects of the health care burden posed by hepatic encephalopathy.
Keywords: Economic burden; Health care costs; Health care resource use; Hepatic encephalopathy.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure The authors in this article have no relevant financial or other relationships to disclose.
Similar articles
-
Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.Transplant Proc. 2006 Dec;38(10):3552-5. doi: 10.1016/j.transproceed.2006.10.107. Transplant Proc. 2006. PMID: 17175328 Clinical Trial.
-
Pharmacoeconomics of hepatic encephalopathy.Pharmacotherapy. 2010 May;30(5 Pt 2):28S-32S. doi: 10.1592/phco.30.pt2.28S. Pharmacotherapy. 2010. PMID: 20412038 Review.
-
Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.Dig Dis Sci. 2007 Mar;52(3):737-41. doi: 10.1007/s10620-006-9442-4. Dig Dis Sci. 2007. PMID: 17245628
-
Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.Am J Med. 2021 Nov;134(11):1330-1338. doi: 10.1016/j.amjmed.2021.06.007. Epub 2021 Jul 7. Am J Med. 2021. PMID: 34242619 Review.
-
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.Pharmacoeconomics. 2018 Jul;36(7):809-822. doi: 10.1007/s40273-018-0641-6. Pharmacoeconomics. 2018. PMID: 29651649 Free PMC article.
Cited by
-
The Management of Hepatic Encephalopathy from Ward to Domiciliary Care: Current Evidence and Gray Areas.J Clin Med. 2023 Dec 27;13(1):166. doi: 10.3390/jcm13010166. J Clin Med. 2023. PMID: 38202173 Free PMC article. Review.
-
Inadequate practices for hepatic encephalopathy management in the inpatient setting.J Hosp Med. 2022 Aug;17 Suppl 1(Suppl 1):S8-S16. doi: 10.1002/jhm.12897. J Hosp Med. 2022. PMID: 35972037 Free PMC article. Review.
-
Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions.World J Gastroenterol. 2022 Nov 7;28(41):5910-5930. doi: 10.3748/wjg.v28.i41.5910. World J Gastroenterol. 2022. PMID: 36405106 Free PMC article. Review.
-
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2. Cochrane Database Syst Rev. 2023. PMID: 37467180 Free PMC article.
-
Ammonia and beyond - biomarkers of hepatic encephalopathy.Metab Brain Dis. 2025 Jan 15;40(1):100. doi: 10.1007/s11011-024-01512-7. Metab Brain Dis. 2025. PMID: 39812958 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources